Does Tremfya Suppress the Immune System?
Yes, Tremfya (guselkumab) is an immunosuppressant. It works by targeting interleukin-23 (IL-23), a protein that drives inflammation in autoimmune diseases like plaque psoriasis, psoriatic arthritis, and ulcerative colitis. By blocking IL-23, Tremfya reduces immune system overactivity that causes these conditions.[1][2]
How Does Tremfya's Mechanism Differ from Other Immunosuppressants?
Unlike broad immunosuppressants such as corticosteroids or methotrexate, which dampen the entire immune response and raise infection risks broadly, Tremfya selectively inhibits the IL-23 pathway. This targeted approach spares other immune functions, potentially lowering some risks while still qualifying it as immunosuppressive due to its modulation of T-cell activity.[1][3]
What Infections Are Patients Asking About with Tremfya?
Tremfya carries warnings for serious infections like tuberculosis and invasive fungal infections, common with immunosuppressants. Clinical trials showed higher infection rates (18% vs. 15% placebo), including upper respiratory issues. Patients on TNF blockers or other biologics face compounded risks if switching.[2][4]
Can You Take Tremfya with Other Immunosuppressants?
Avoid combining with live vaccines or strong systemic immunosuppressants like biologics targeting TNF or IL-17, due to heightened infection risk. Prescribers screen for latent TB before starting.[2]
When Does Tremfya's Patent Expire?
Core patents for guselkumab expire around 2032-2033 in the US, with some formulation patents extending to 2034. Challenges from biosimilar developers like Samsung Bioepis are ongoing.[5]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf
[2] Tremfya Prescribing Information: https://www.tremfya.com/
[3] Janssen Medical Information: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA/pi.pdf
[4] ClinicalTrials.gov (NCT02207231): https://clinicaltrials.gov/study/NCT02207231
[5] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/TREMFYA